Sergi Vaqué-Salsench

Sergi Vaqué-Salsench

Auto-generated profile, based on publicly available information

Sergi Vaqué-Salsench

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
LRLuis Gerardo Rodríguez-Lobato
Luis Gerardo Rodríguez-Lobato
OCOriol Cardús
Oriol Cardús
JMJoan Mañé-Pujol
Joan Mañé-Pujol
ABAnthony Battram
Anthony Battram
SVSergi Vaqué-Salsench
Sergi Vaqué-Salsench
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has revolutionized the prognosis of patients with relapsed/refractory multiple myeloma. Regrettably, despite unprecedented overall response rates achieved with this approach, most patients eventually relapse. One of the primary reasons for this is the complete loss or reduced expression of BCMA on the malignant plasma cell surface. Consequently, new therapeutic targets are under investigation. Another potential therapeutic approach involves the use of CAR T cells targeting two tumor antigens. In this study, we developed and validated a monospecific CAR targeting CD229, which was effective in in vitro and in vivo NOD.Cg-Prkdcscid Il2rdtm1Wjl/SzJ mouse models with both homogeneous and heterogeneous BCMA expression. Additionally, we created a bicistronic CAR T cell targeting both CD229 and BCMA, which demonstrated efficacy in models with homogeneous BCMA expression, in heterogeneous models featuring small clonal populations with biallelic BCMA deletion, and in cases with reduced BCMA expression both in vivo and in vitro. Regarding “on-target off-tumor toxicity,” no fratricide was observed among CAR T cells, but there was a limited elimination of nonactivated T cells. The immune pressure exerted by anti-CD229 CAR T cells led to the loss of the CD229 antigen expression in some instances. In summary, this work underscores the potential utility of CD229 alone or in combination with BCMA as an immunotherapeutic target in multiple myeloma, especially in cases marked by diminished or absent BCMA expression.

2 September 2025
Verified
Other
Open access
PDF file
LRLuis Gerardo Rodríguez-Lobato
Luis Gerardo Rodríguez-Lobato
OCOriol Cardús
Oriol Cardús
JMJoan Mañé-Pujol
Joan Mañé-Pujol
ABAnthony Battram
Anthony Battram
SVSergi Vaqué-Salsench
Sergi Vaqué-Salsench
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
Cytokine production (IFNγ and IL-2) of CAR T-cells in co-culture with K562 cell lines with different expression of CD229 antigen tumor cells at the 24-hr time point measured by ELISA.

2 September 2025
Verified
Other
Open access
PDF file
LRLuis Gerardo Rodríguez-Lobato
Luis Gerardo Rodríguez-Lobato
OCOriol Cardús
Oriol Cardús
JMJoan Mañé-Pujol
Joan Mañé-Pujol
ABAnthony Battram
Anthony Battram
SVSergi Vaqué-Salsench
Sergi Vaqué-Salsench
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
Generation of a cell line with low BCMA expression (MM.1S BCMA dim) from MM1S BCMA KO cells with an incomplete KO

2 September 2025
Verified
Other
Open access
PDF file
RLRodríguez- Lobato
Rodríguez- Lobato
LGLuis Gerardo
Luis Gerardo
OCOriol Cardús
Oriol Cardús
JMJoan Mañé-Pujol
Joan Mañé-Pujol
ABAnthony Battram
Anthony Battram
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
Clones of the K562 tumor cell line with different CD229 expression gradient

2 September 2025
Verified
Other
Open access
PDF file
LRLuis Gerardo Rodríguez-Lobato
Luis Gerardo Rodríguez-Lobato
OCOriol Cardús
Oriol Cardús
JMJoan Mañé-Pujol
Joan Mañé-Pujol
ABAnthony Battram
Anthony Battram
SVSergi Vaqué-Salsench
Sergi Vaqué-Salsench
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
Quantification of tumor burden by bioluminescence imaging over time of tumor cell infusion and luminescence at week 7 of each group.

2 September 2025
Verified
Other
Open access
PDF file
LRLuis Gerardo Rodríguez-Lobato
Luis Gerardo Rodríguez-Lobato
OCOriol Cardús
Oriol Cardús
JMJoan Mañé-Pujol
Joan Mañé-Pujol
ABAnthony Battram
Anthony Battram
SVSergi Vaqué-Salsench
Sergi Vaqué-Salsench
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
BCMA and CD229 antigen expression on wild-type and BCMA knock-out tumor cells.